Cargando…
Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters
Personalized medicine using targeted therapies has revolutionized the management of non-small cell lung cancer (NSCLC) in the past decade. The discovery that sensitizing epidermal growth factor receptor (EGFR) mutations are predictive for therapeutic benefit from EGFR tyrosine kinase inhibitors (TKI...
Autores principales: | Gandhi, Shipra, Kapoor, Ankita, Dy, Grace |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164712/ https://www.ncbi.nlm.nih.gov/pubmed/32313757 http://dx.doi.org/10.7759/cureus.7316 |
Ejemplares similares
-
A Rare Case of Missing Primary in Metastatic Renal Cell Carcinoma
por: Kapoor, Ankita, et al.
Publicado: (2020) -
Pseudocirrhosis in Chronic Budd Chiari Syndrome With Janus Tyrosine Kinase 2 (JAK2) Mutation
por: Lakshmanan, Seetha, et al.
Publicado: (2020) -
A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib
por: Bhuiyan, Sakil, et al.
Publicado: (2021) -
Complete Remission of Bone Metastases in Renal Cell Carcinoma with Nivolumab
por: Vuyyala, Sowjanya, et al.
Publicado: (2019) -
Two Unusual Mutations in the Epidermal Growth Factor Receptor Gene in a Patient With Lung Adenocarcinoma
por: Zapata Laguado, Martin, et al.
Publicado: (2022)